Tmod-24. a novel xenograft model reveals a gene cascade defining a mesenchymal transition during the evolution of resistance to anti-angiogenic therapy

CONCLUSION:These results suggest a mesenchymal and pro-angiogenic response to bevacizumab supported by multiple converging pathways involving inflammation, hypoxia, and ECM remodeling. Strategies preventing the evolution of these responses should be developed and tested in the context of our novel xenograft model to improve the durability of therapeutic response.

Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Jahangiri, A., Chen, W., Yagnik, G., Sidorov, M., Rick, J., Kuang, R., Lay, M. D., Flanigan, P. M., Aghi, M. Tags: TUMOR MODELS Source Type: research